Angiotensin II, platelets and oxidative stress

Journal of Hypertension

Volumn 22, Issue 6, 2004, Pages 1085-1086

  Duprez, Daniel A ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN; NITRIC OXIDE;

CARDIOVASCULAR DISEASE; CELL ADHESION; CORONARY ARTERY DISEASE; DISEASE COURSE; EDITORIAL; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; VASCULAR DISEASE;

EID: 2642517094     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200406000-00005     Document Type: Editorial

References (16)

1. Libby P, Ridker PM. Novel inflammatory markers of coronary risk. Theory versus practice. Circulation 1999; 100:1148-1150.
2. Lip GYH, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation 2000; 101:218-220.
3. Torsellini A, Becucci A, Citi S, Cozzolino F, Guidi G, Lombardi V, et al. Effects of pressure excursions on human platelets: in vitro studies on β-thromboglobulin (β-TG) and platelet factor 4 (PF4) release and on platelet sensitivity to ADP-aggregation. Haematologica 1982; 67:860-866.
4. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT 1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40:521-527.
5. Fox KM, EURopean trial. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
6. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22:1845-1851.
7. Strawn WB, Ferrario CM. Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 2002; 13:505-512.
8. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000; 101:2206-2212.
9. Griendling KK, Sorescu D, Ushio-Fukai M. NA(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86:494-501.
10. Loscalzo J. Oxidative stress in endothelial cell dysfunction and thrombosis. Pathophysiol Haemost Thromb 2002; 32:359-360.
11. Germano G, Sanguigni V, Pignatelli P, Caccese D, Lenti L, Ragazzo M, et al. Enhanced platelet release of superoxide anion in systemic hypertension: role of AT 1 receptors. J Hypertens 2004; 22:1151-1156.
12. Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, Jimenez AM, Gonzalez-Fernandez F, Rico LA, et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17:447-452.
13. Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 2000; 292:238-246.
14. Zhuo JL. Monocyte chemoattractant protein-1: a key mediator of angiotensin II-induced target organ damage in hypertensive heart disease. J Hypertens 2004; 22:451-455.
15. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42:905-910.
16. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002; 89:18A-25A.